Metrics as of 10/13/2026, 06:31 PM (Berlin time), refresh in progress.
Relmada Therapeutics Stock
Relmada Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sergio Traversa
- Employees
- 17
- Market cap
- $352 M
- IPO
- 20/06/2014
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive…
Relmada Therapeutics stock: price history
1D
-4.3%
1W
+2.4%
1M
-25.7%
6M
-53.3%
YTD
-30.4%
1Y
+66.3%
2Y
+306.0%
5Y
-35.8%
10Y
+320.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~19% weaker price swings than usual
Ask the agents about Relmada Therapeutics
Analyst assessment of Relmada Therapeutics
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
5
BUY
2
HOLD
1
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 20/03/2026
Relmada Therapeutics stock metrics
P/E
-3.65
P/B
1.83
EV/EBITDA
-5.51
RETURN ON EQUITY
-6.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.2%
FLOAT SHARES
90,417,382
AVG. DAILY VOLUME (30D)
1,364,016
Insider transactions (SEC)
TRAVERSA SERGIO
TRAVERSA SERGIO
Shenouda Maged
Shenouda Maged
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Relmada Therapeutics stock
What does Relmada Therapeutics do?
Relmada Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sergio Traversa, the company employs around 17 people.
The IPO was on 20/06/2014; the stock trades on NASDAQ under the ticker RLMD.
What do analysts say about Relmada Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 20/03/2026).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Relmada Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -19% stronger than usual.
Does Relmada Therapeutics pay a dividend?
No, Relmada Therapeutics currently does not pay a dividend.
Which stocks are comparable to Relmada Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Relmada Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Relmada Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.